Repado is proud to congratulate NU-RISE on achieving U.S. FDA clearance for its PRO-DOSE system, an advanced real-time dosimetry solution for radiotherapy treatment verification.
The PRO-DOSE device provides real-time measurement of radiation doses delivered during brachytherapy procedures, enabling clinicians to monitor dose and dose rate directly and accurately. The system combines calibrated probes with dedicated hardware and software to provide immediate feedback during patient treatment.
Repado contributed to this milestone by supporting the development the PRO-DOSE software, responsible for data acquisition, high throughput signal interpretation, and real-time visualization. The collaboration ensured that the software met the highest standards of reliability, cybersecurity, and regulatory compliance required for medical device software, developed under an enhanced documentation level in accordance with FDA expectations.
“Our collaboration with NU-RISE has been a true partnership; built on mutual trust, technical excellence, and a shared mission to advance safer cancer treatment”, said Kostas Delakouridis, CEO at Repado. “Seeing PRO-DOSE achieve FDA clearance is a proud moment for both teams and a testament to the strength of cross-disciplinary collaboration.”
“The Repado team’s technical excellence, responsiveness, and shared commitment to quality were key to turning our vision into a robust and compliant product that meets a real clinical need. We’re truly grateful for this partnership and the collaboration behind it” said Joana Melo, CEO & Founder at NU-RISE.
This milestone marks the culmination of years of collaborative R&D, rigorous testing, and alignment across engineering, quality, and regulatory disciplines. With FDA clearance secured, NU-RISE is now positioned to advance its commercial strategy and bring PRO-DOSE to clinical settings across the United States.
Repado congratulates the entire NU-RISE team on this remarkable achievement and looks forward to continued collaboration in bringing innovative medical technologies to market.
